Mangoceuticals, Inc.
MGRX
$1.11
$0.043.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -36.88% | 3.00% | -48.95% | -56.96% | -45.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.88% | 3.00% | -48.95% | -56.96% | -45.60% |
| Cost of Revenue | -34.32% | -16.27% | -29.24% | -75.34% | -49.60% |
| Gross Profit | -38.45% | 28.80% | -57.87% | -43.83% | -42.81% |
| SG&A Expenses | 376.79% | 138.92% | 47.40% | -26.96% | -6.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 364.06% | 132.59% | 45.30% | 0.07% | -8.54% |
| Operating Income | -399.61% | -142.53% | -54.37% | -6.28% | 2.65% |
| Income Before Tax | -281.00% | -126.48% | -104.41% | 24.12% | -11.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -281.00% | -126.48% | -104.41% | 24.12% | -11.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 20.00% | -100.00% | -- | -- | -- |
| Net Income | -281.06% | -126.51% | -104.40% | 24.13% | -11.10% |
| EBIT | -399.61% | -142.53% | -54.37% | -6.28% | 2.65% |
| EBITDA | -398.06% | -106.39% | -36.10% | 25.69% | 2.27% |
| EPS Basic | 39.70% | 60.52% | 29.93% | 45.01% | 32.82% |
| Normalized Basic EPS | 33.41% | 61.43% | 29.92% | 62.02% | 41.44% |
| EPS Diluted | 39.70% | 60.52% | 29.93% | 45.01% | 32.82% |
| Normalized Diluted EPS | 33.41% | 61.43% | 29.92% | 62.02% | 41.44% |
| Average Basic Shares Outstanding | 472.27% | 473.76% | 191.70% | 99.73% | 89.69% |
| Average Diluted Shares Outstanding | 472.27% | 473.76% | 191.70% | 99.73% | 89.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |